Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celebrex Set For Rebound; Silver Lining For Pfizer After Bextra Pulled

Executive Summary

Celebrex is in a good position to reclaim its position as the leading anti-arthritic therapy following the conclusion of FDA's safety review of the non-steroidal anti-inflammatory drug class

You may also be interested in...



Pfizer, Elan Performances Suggest Investor Comfort With Drug Safety Issues

Increased confidence in Elan/Biogen's ability to return the multiple sclerosis therapy Tysabri to the market by the fall could be a signal that pharma and biotech companies have turned the corner on drug safety issues

Pfizer, Elan Performances Suggest Investor Comfort With Drug Safety Issues

Increased confidence in Elan/Biogen's ability to return the multiple sclerosis therapy Tysabri to the market by the fall could be a signal that pharma and biotech companies have turned the corner on drug safety issues

Celebrex, NSAID Labeling Must Include Skin Reactions Warning, FDA Says

FDA is requiring labeling for non-steroidal anti-inflammatory drugs include a warning on skin reactions, in addition to a boxed warning on cardiovascular and gastrointestinal risk

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS045634

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel